# Forte Biosciences Inc - Investor Relations - News
Canonical URL: https://biopharmsignal.com/news/FBRX/forte-biosciences-inc-investor-relations-news-934e172e
Ticker: FBRX
Company: Forte Biosciences
Source: Forte Biosciences
Published: 2026-07-09 00:00 EST
Original Source URL: https://www.fortebiorx.com/investor-relations/news/default.aspx
## Summary

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested...

## Article Body
To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Forte Biosciences Inc, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Forte Biosciences Inc to send you the requested Investor Email Alert updates.

* Required
## Recent Company News
- 2026-07-09 00:00 EST — [Forte Biosciences Inc - Investor Relations - News](https://biopharmsignal.com/news/FBRX/forte-biosciences-inc-investor-relations-news-934e172e) — Source: Forte Biosciences
- 2025-12-22 00:00 EST — [Forte Biosciences Inc - Investor Relations - News](https://biopharmsignal.com/news/FBRX/forte-biosciences-inc-investor-relations-news-39d4d271) — Source: Forte Biosciences
- 2024-11-25 00:00 EST — [Forte Biosciences Inc - Investor Relations - News](https://biopharmsignal.com/news/FBRX/forte-biosciences-inc-investor-relations-news-95ee0794) — Source: Forte Biosciences
- 2023-12-01 00:00 EST — [Forte Biosciences Inc - Investor Relations - News](https://biopharmsignal.com/news/FBRX/forte-biosciences-inc-investor-relations-news-4578414f) — Source: Forte Biosciences
- 2022-11-14 00:00 EST — [Forte Biosciences Inc - Investor Relations - News](https://biopharmsignal.com/news/FBRX/forte-biosciences-inc-investor-relations-news-47bb286a) — Source: Forte Biosciences
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)